138 related articles for article (PubMed ID: 25483927)
1. Synergistic induction of apoptosis by mapatumumab and anthracyclines in human bladder cancer cells.
Ahmed SM; Wu X; Jin X; Zhang X; Togo Y; Suzuki T; Li Y; Kanematsu A; Nojima M; Yamamoto S; Sugimoto M; Kakehi Y
Oncol Rep; 2015 Feb; 33(2):566-72. PubMed ID: 25483927
[TBL] [Abstract][Full Text] [Related]
2. Enhancement of lexatumumab-induced apoptosis in human solid cancer cells by Cisplatin in caspase-dependent manner.
Wu XX; Kakehi Y
Clin Cancer Res; 2009 Mar; 15(6):2039-47. PubMed ID: 19276256
[TBL] [Abstract][Full Text] [Related]
3. Delineation of apoptotic genes for synergistic apoptosis of lexatumumab and anthracyclines in human renal cell carcinoma cells by polymerase chain reaction array.
Jin X; Wu XX; Jin C; Inui M; Sugimoto M; Kakehi Y
Anticancer Drugs; 2012 Apr; 23(4):445-54. PubMed ID: 22205156
[TBL] [Abstract][Full Text] [Related]
4. Enhancement of death receptor 4-mediated apoptosis and cytotoxicity in renal cell carcinoma cells by anisomycin.
Li Y; Wu X; Jin X; Wang J; Togo Y; Suzuki T; Hashimoto T; Yamada Y; Nakanishi Y; Kanematsu A; Nojima M; Kakehi Y; Yamamoto S
Anticancer Drugs; 2017 Feb; 28(2):180-186. PubMed ID: 27879498
[TBL] [Abstract][Full Text] [Related]
5. Enhancement of death receptor 4 mediated apoptosis and cytotoxicity in renal cell carcinoma cells by subtoxic concentrations of doxorubicin.
Jin X; Wu XX; Abdel-Muneem Nouh MA; Kakehi Y
J Urol; 2007 May; 177(5):1894-9. PubMed ID: 17437844
[TBL] [Abstract][Full Text] [Related]
6. Enhanced sensitivity of bladder cancer cells to tumor necrosis factor related apoptosis inducing ligand mediated apoptosis by cisplatin and carboplatin.
Mizutani Y; Nakao M; Ogawa O; Yoshida O; Bonavida B; Miki T
J Urol; 2001 Jan; 165(1):263-70. PubMed ID: 11125422
[TBL] [Abstract][Full Text] [Related]
7. Sensitization of human bladder cancer cells to Fas-mediated cytotoxicity by cis-diamminedichloroplatinum (II).
Mizutani Y; Yoshida O; Bonavida B
J Urol; 1998 Aug; 160(2):561-70. PubMed ID: 9679929
[TBL] [Abstract][Full Text] [Related]
8. Synergistic cytotoxicity and apoptosis by Apo-2 ligand and adriamycin against bladder cancer cells.
Mizutani Y; Yoshida O; Miki T; Bonavida B
Clin Cancer Res; 1999 Sep; 5(9):2605-12. PubMed ID: 10499639
[TBL] [Abstract][Full Text] [Related]
9. Expression of TRAIL, DR4, and DR5 in bladder cancer: correlation with response to adjuvant therapy and implications of prognosis.
Li Y; Jin X; Li J; Jin X; Yu J; Sun X; Chu Y; Xu C; Li X; Wang X; Kakehi Y; Wu X
Urology; 2012 Apr; 79(4):968.e7-15. PubMed ID: 22244504
[TBL] [Abstract][Full Text] [Related]
10. Human agonistic antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 2 induces cytotoxicity and apoptosis in prostate cancer and bladder cancer cells.
Shimada O; Wu X; Jin X; Nouh MA; Fiscella M; Albert V; Matsuda T; Kakehi Y
Urology; 2007 Feb; 69(2):395-401. PubMed ID: 17320696
[TBL] [Abstract][Full Text] [Related]
11. Cell death via DR5, but not DR4, is regulated by p53 in myeloma cells.
Surget S; Chiron D; Gomez-Bougie P; Descamps G; Ménoret E; Bataille R; Moreau P; Le Gouill S; Amiot M; Pellat-Deceunynck C
Cancer Res; 2012 Sep; 72(17):4562-73. PubMed ID: 22738917
[TBL] [Abstract][Full Text] [Related]
12. Low concentrations of doxorubicin sensitizes human solid cancer cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-receptor (R) 2-mediated apoptosis by inducing TRAIL-R2 expression.
Wu XX; Jin XH; Zeng Y; El Hamed AM; Kakehi Y
Cancer Sci; 2007 Dec; 98(12):1969-76. PubMed ID: 17922852
[TBL] [Abstract][Full Text] [Related]
13. Cisplatin-mediated c-myc overexpression and cytochrome c (cyt c) release result in the up-regulation of the death receptors DR4 and DR5 and the activation of caspase 3 and caspase 9, likely responsible for the TRAIL-sensitizing effect of cisplatin.
Zhu X; Zhang K; Wang Q; Chen S; Gou Y; Cui Y; Li Q
Med Oncol; 2015 Apr; 32(4):133. PubMed ID: 25796504
[TBL] [Abstract][Full Text] [Related]
14. Phytosphingosine in combination with TRAIL sensitizes cancer cells to TRAIL through synergistic up-regulation of DR4 and DR5.
Choi SY; Kim MJ; Chung HY; Lee SJ; Jang YJ
Oncol Rep; 2007 Jan; 17(1):175-84. PubMed ID: 17143496
[TBL] [Abstract][Full Text] [Related]
15. TRAIL-induced apoptosis and expression of death receptor TRAIL-R1 and TRAIL-R2 in bladder cancer cells.
Szliszka E; Mazur B; Zydowicz G; Czuba ZP; Król W
Folia Histochem Cytobiol; 2009; 47(4):579-85. PubMed ID: 20430723
[TBL] [Abstract][Full Text] [Related]
16. A novel anti-DR5 chimeric antibody and epirubicin synergistically suppress tumor growth.
Qiu Y; Zhang Z; Shi J; Liu S; Liu Y; Zheng D
IUBMB Life; 2012 Sep; 64(9):757-65. PubMed ID: 22815059
[TBL] [Abstract][Full Text] [Related]
17. Repeated treatment with subtoxic doses of TRAIL induces resistance to apoptosis through its death receptors in MDA-MB-231 breast cancer cells.
Yoshida T; Zhang Y; Rivera Rosado LA; Zhang B
Mol Cancer Res; 2009 Nov; 7(11):1835-44. PubMed ID: 19843632
[TBL] [Abstract][Full Text] [Related]
18. Sensitization of human renal cell carcinoma cell lines to TRAIL-induced apoptosis by anthracyclines.
Wu XX; Ogawa O; Kakehi Y
Int J Urol; 2004 Mar; 11(3):164-70. PubMed ID: 15009365
[TBL] [Abstract][Full Text] [Related]
19. Targeting pro-apoptotic trail receptors sensitizes HeLa cervical cancer cells to irradiation-induced apoptosis.
Maduro JH; de Vries EG; Meersma GJ; Hougardy BM; van der Zee AG; de Jong S
Int J Radiat Oncol Biol Phys; 2008 Oct; 72(2):543-52. PubMed ID: 18793956
[TBL] [Abstract][Full Text] [Related]
20. Induction of G1 cell cycle arrest and apoptosis by berberine in bladder cancer cells.
Yan K; Zhang C; Feng J; Hou L; Yan L; Zhou Z; Liu Z; Liu C; Fan Y; Zheng B; Xu Z
Eur J Pharmacol; 2011 Jul; 661(1-3):1-7. PubMed ID: 21545798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
